Form 4: Phathom Pharmaceuticals Director James Topper Reports Stock and Option Awards

Director James Topper reports acquisition of stock and option awards from Phathom Pharmaceuticals.

Summary

• On May 23, 2024, James Topper, a director of Phathom Pharmaceuticals, reported transactions involving the company's stock.
• Topper acquired 10,500 shares of common stock through Restricted Stock Units (RSUs) granted under the Non-Employee Director Compensation Program.
• These RSUs will vest on the earlier of the first anniversary of the grant date or the next annual meeting, contingent upon Topper's continued service on the board.
• Each RSU represents the right to receive one share of Phathom Pharmaceuticals common stock.
• Topper also acquired an option to buy 17,500 shares of common stock at an exercise price of $10.30, also vesting on the earlier of the first anniversary of the grant date or the next annual meeting, contingent upon continued service.
• Topper also indirectly owns shares through Frazier Life Sciences IX, L.P. (5,827,415 shares), FHMLS IX, L.L.C. (1 share), and Topper Group III LLC (3,912 shares).

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The filing reflects standard compensation practices and aligns director interests with shareholders. There are no immediate negative implications.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service on the board.

Future Outlook

The RSUs and stock options vest on the earlier of the first anniversary of the grant date or the next annual meeting, contingent upon continued service on the board.

Industry Context

This filing is a routine disclosure of stock and option awards to a company director, common in the pharmaceutical industry as part of executive compensation packages.

Comparison to Industry Standards

• Stock option and RSU grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize similar equity-based compensation to align director and shareholder interests.
• The vesting schedules are also typical, often tied to continued service and/or company performance.

Stakeholder Impact

• The stock and option awards align the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates